Moderna agreed to pay $950 million upfront to Arbutus Biopharma and Roivant’s Genevant to settle long‑running patent claims tied to its Covid‑19 mRNA vaccine. The settlement closes a multi‑year dispute over delivery technologies and intellectual property around Moderna’s platform. Under the deal Moderna also accepted contingent payouts and may owe additional amounts depending on appeals and indemnification outcomes tied to government programs. The settlement resolves major legal overhangs that had shadowed Moderna’s pandemic vaccine success. For companies litigating over platform technology, the agreement highlights the high stakes of intellectual property in the mRNA era and may shape future licensing and collaboration strategies across vaccine and LNP delivery developers.